ArticleIJTLD open2026
Key operational challenges at a programmatic level to achieve optimal use of the GeneXpert platform.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough Xpert MTB/RIF Ultra (Ultra) has revolutionised TB diagnosis, operational challenges can significantly undermine its benefits. This study examined operational experiences and challenges associated with Ultra use across Rwanda's health care settings.
methodsWe conducted a cross-sectional survey across 53 GeneXpert testing centres between October and December 2024. The survey addressed machine usage, sample processing timelines, and technical challenges through structured interviews with laboratory managers and operators.
resultsWhile 41% of sites processed samples within 5 h, 55% experienced delays exceeding 24 h due to high volumes and limited capacity. Four labs (8%) reported significant delays (>8 h) processing sputum with sample reagent. Modules failures occurred in 81% of facilities within the preceding year, with most experiencing infrequent failures and one site experiencing more than six annually. Connectivity issues with internet and/or 'DataToCare' affected 17% of sites, causing workflow delays. Equipment capacity constraints were identified in 30% of sites, particularly affecting facilities managing dual TB and HIV/hepatitis testing, while 9% reported staffing shortages.
conclusionDespite successful nationwide deployment, operational challenges limit Ultra's full potential. Strategic machine allocation, upgraded connectivity, and improved preventive maintenance represent key intervention areas. These findings offer valuable insights optimising rapid molecular diagnostic use in similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.